All the top Biotech & Pharma news in one daily newsletter.

Want to understand how these updates are formatted? Check-out the FAQ.

Have any feedback? I’d love to hear you from - connect with me on LinkedIn. 📣

THE GOOD
Business Development & Partnerships

Rovi, Bristol Myers Squibb strike Phoenix facility acquisition plus $250M five-year manufacturing partnership
Manufacturing agreement, acquisition, antibody-drug conjugates, monoclonal antibodies, milestone payments - Read more

Boryung acquires Sanofi's Taxotere chemotherapy rights across 19 markets for up to $205M
Licensing deal, oncology, small molecule, manufacturing, global, milestone payments - Read more

Nxera Pharma lands $10M milestone payment from AbbVie as part of neurological disease collaboration
Research collaboration, neurological, drug discovery, milestone payments, small molecule - Read more

THE GOOD
Clinical Trials

Merck & Co.’s Winrevair shows 76% reduction in clinical worsening in Ph3 trial for newly diagnosed pulmonary arterial hypertension
Protein therapy, cardiovascular, activin signaling inhibitor, pulmonary arterial hypertension, sotatercept - Read more

Opus Genetics reports pediatric gene therapy data for Leber Congenital Amaurosis Type 5, plans FDA discussions
Gene therapy, neurological, AAV vector, Leber congenital amaurosis, pediatric population, rare disease - Read more

AC Immune's ACI-35.030 Tau-targeting therapy shows strong immune response in Ph1b/2a early Alzheimer's disease trial
Neurological, active immunotherapy, Alzheimer disease, tau protein, phosphorylated tau - Read more

Kardigan reports positive Ph2a results for danicamtiv cardiac myosin activator in genetic dilated cardiomyopathy
Small molecule, cardiovascular, cardiac myosin activator, dilated cardiomyopathy, sarcomeric mutations - Read more

PRESENTED BY PROMOVEO HEALTH
Contract Sales Reps = Fast Deployment + Lower Cost

We've built 100+ pharma sales teams for companies of all sizes, and we can help you.

We build agile field teams that scale based on your needs - all with fast deployment + lower cost than full-time reps.

See how flexible can work - click here to learn more.

✅ More Good News ✅

THE GOOD
Fundraises

ARS Pharmaceuticals secures $250M loan facility, accelerating neffy epinephrine commercialization
Allergy/anaphylaxis, epinephrine delivery, needle-free technology, commercial-stage - Read more

THE GOOD
Mergers & Acquisitions

Barinthus Bio merges with Clywedog Therapeutics in reverse deal advancing diabetes, autoimmune assets
Immunotherapy, diabetes, reverse mergers - Read more

THE GOOD
Politics & Policy

Pfizer signs first US drug pricing deal matching lower international prices under “Most Favoured Nation” scheme under Trump administration + direct to consumer on forthcoming “TrumpRx” website
Multiple therapeutic areas, drug pricing, strategic, cost reduction, major transaction - Read more

THE GOOD
Regulatory

EMA publishes draft paper encouraging patient experience data inclusion in drug regulatory decisions
Patient experience data, draft guidance, drug approval process - Read more

THE GOOD
Strategic Plans

AnaptysBio plans spinoff splitting clinical pipeline from Jemperli royalty businesses into separate companies
Monoclonal antibody, oncology, strategic, major transaction, financial - Read more

AstraZeneca plans direct NYSE listing to replace Nasdaq ADRs, harmonizing share structure globally
Stock listing, publicly traded - Read more

PRESENTED BY YOU?
Get the attention of 2200+ Biotech & Pharma Professionals 🤩

Do you offer a biotech/pharma-focused product or service?

Or looking to get investor/analyst interest on your budding start-up?

Considering sponsoring TLDR Biotech to get in-front of an engaged audience of biotech & pharma-focused professionals.

Just reply to this email* or message me on LinkedIn to learn more.

*If you’re reading this on the web version, email [email protected]

THE BAD
Business Development & Partnerships

Novo Nordisk terminates $598M Heartseed cell therapy partnership amid strategic restructuring
Cell therapy, research collaboration, heart failure - Read more

THE BAD
Clinical Trials

Moonlake's sonelokimab shows mixed Ph3 results in hidradenitis suppurativa, missing endpoints despite statistical significance
Monoclonal antibody, hidradenitis suppurativa, IL-17 inhibitor, inflammatory skin disease - Read more

Orion's ODM-105 tasipimidine fails Ph2 primary endpoint for insomnia treatment, company discontinues development program
Small molecule, neurological, insomnia, sleep disorders - Read more

THE BAD
Earnings & Finance

Morgan Stanley downgrades Novo Nordisk stock citing GLP-1 demand concerns and Alzheimer's treatment doubts
GLP-1 agonist, metabolic disease, financial, competitive, strategic - Read more

THE BAD
Lawsuits

Indivior discontinues Opvee marketing following New York settlement over unauthorized promotional activities to officials
Opioid reversal drug, opioid addiction, opioid overdose, access - Read more

THE BAD
Layoffs

Sutro Biopharma cuts third of remaining workforce in second round of layoffs this year
Drug pricing, strategic, financial, regulatory, competitive - Read more

THE UGLY
Regulatory

FDA's Tidmarsh, in an unprecedented move, publicly criticizes Aurinia's Lupkynis approval in now-deleted LinkedIn post, sending stock tumbling
Immunosuppressant, autoimmune, regulatory commentary - Read more

FDA to be impacted by (now in effect) USA government shutdown, with 86% staff retained but new drug applications halted
Government shutdown, public agency - Read more

You’re all caught up on the latest Pharma & Biotech News!

TLDR Biotech wants to hear from you! 📣

Have comments/questions/complaints about this newsletter?
Send me an email - I want your brutally honest feedback. 📝

If you find the content useful and think a colleague would too, please share TLDR Biotech with them! ♻️

And lastly - connect with me on LinkedIn!

Disclaimer: Content, news, research, tools, and mention of stock or tradeable securities are for educational and illustrative purposes only and do not imply a recommendation or solicitation to buy or sell a particular security or to engage in any particular investment strategy. Read the full terms & conditions here